Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy

Executive Summary

Watson Pharmaceuticals says the outlook for its most recent launches, Rapaflo and Gelnique, is much improved in 2010, now that it has revamped its branded sales strategy and secured better insurance coverage for these products
Advertisement

Related Content

Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon
Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon
Watson Acquires Arrow Group And Expands Its Global Footprint
Watson Acquires Arrow Group And Expands Its Global Footprint
Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?
Rapaflo Approved For BPH; Watson Will Stress Unique Selectivity

Topics

Advertisement
UsernamePublicRestriction

Register

PS051936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel